Combination sedative-antipsychotic

This page covers all Combination sedative-antipsychotic drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting GABA-A receptor, dopamine D2 receptor, muscarinic acetylcholine receptor.

Targets

GABA-A receptor, dopamine D2 receptor, muscarinic acetylcholine receptor

Marketed (1)

• Valium + Akineton + Dehydrobenzperidol + Atropine sulfate · Universitaire Ziekenhuizen KU Leuven · Psychiatry/Neurology
  This combination drug produces sedation, muscle relaxation, and antipsychotic effects through multiple central nervous system depressants and anticholinergic agents acting simultaneously.

Patent intelligence

• combination sedative antipsychotic patent landscape — aggregated cliff calendar, attackable patents, originator estates